55
Participants
Start Date
February 12, 2019
Primary Completion Date
March 31, 2023
Study Completion Date
March 31, 2023
Canakinumab 150mg/ml solution for injection
Canakinumab 150mg/ml solution for injection
Placebo
100ml 5% Dextrose
University Hospitals Bristol NHS Foundation Trust, Bristol
Queen Elizabeth University Hospital, Glasgow
Leeds Teaching Hospitals NHS Trust, Leeds
Aintree University Hospital, Liverpool
Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool
Chelsea and Westminster Hospital NHS Foundation Trust, London
King's College Hospital NHS Foundation Trust, London
Royal Free London NHS Foundation Trust, London
St George's University Hospitals NHS Foundation Trust, London
The Newcastle Upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne
Nottingham University Hospitals NHS Trust, Nottingham
Plymouth Hospitals NHS Trust, Plymouth
University Hospital Southampton NHS Foundation Trust, Southampton
Glasgow Royal Infirmary, Greater Glasgow & Clyde, Glasgow
Imperial College Healthcare NHS Foundation Trust, London
John Radcliffe Hospital, Oxford University NHS Foundation Trust, Oxford
Collaborators (1)
Novartis Pharmaceuticals
INDUSTRY
Imperial College London
OTHER